Free Trial

Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Sold by Exchange Traded Concepts LLC

Dynavax Technologies logo with Medical background

Exchange Traded Concepts LLC decreased its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 21.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 128,078 shares of the biopharmaceutical company's stock after selling 34,648 shares during the period. Exchange Traded Concepts LLC owned about 0.10% of Dynavax Technologies worth $1,661,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVAX. Russell Investments Group Ltd. increased its stake in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 1,169 shares during the period. Smartleaf Asset Management LLC increased its stake in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 2,034 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Dynavax Technologies in the fourth quarter worth $35,000. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Dynavax Technologies in the fourth quarter worth $71,000. Finally, GAMMA Investing LLC grew its position in shares of Dynavax Technologies by 88.4% during the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock worth $100,000 after buying an additional 3,627 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. JMP Securities dropped their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of "Hold" and a consensus price target of $24.00.

View Our Latest Stock Report on Dynavax Technologies

Dynavax Technologies Stock Down 3.0%

DVAX stock traded down $0.31 during trading on Friday, reaching $9.99. 5,233,685 shares of the company traded hands, compared to its average volume of 2,176,187. Dynavax Technologies Corporation has a 12 month low of $9.22 and a 12 month high of $14.63. The business has a 50 day simple moving average of $10.30 and a 200 day simple moving average of $12.06. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -19.21 and a beta of 1.06. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.84 and a current ratio of 11.93.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. The company had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. On average, equities research analysts anticipate that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

(Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Read More

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Should You Invest $1,000 in Dynavax Technologies Right Now?

Before you consider Dynavax Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.

While Dynavax Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines